Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy

OBJECTIVES: Many people with type 2 diabetes experience clinical inertia, remaining in poor glycaemic control on oral glucose-lowering medications rather than intensifying treatment with a glucagon-like peptide-1 receptor agonist, despite an efficacious, orally administered option, oral semaglutide,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Hongye, Berry, Sasha, Malkin, Samuel Joseph Paul, Hunt, Barnaby, Bain, Stephen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Health Economics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546165/
https://www.ncbi.nlm.nih.gov/pubmed/37775297
http://dx.doi.org/10.1136/bmjopen-2022-070473

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10546165/
https://www.ncbi.nlm.nih.gov/pubmed/37775297
http://dx.doi.org/10.1136/bmjopen-2022-070473

Ejemplares similares